Geographic atrophy

Screening patient for AMD
#Clinical trial #Geographic atrophy

First patient dosed in trial of Geographic Atrophy treatment 

The first patient has been dosed in a first-in-human clinical trial of a treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD).  CTx001, developed by biotechnology company Complement Therapeutics, is being evaluated in the Phase I/II Opti-GAIN study evaluating its safety, tolerability and preliminary efficacy. … Read More

#News

Screening patient for AMD
#AMD #Complement Therapeutics #FDA #Geographic atrophy

FDA fast tracks geographic atrophy treatment 

The US Food and Drug Administration (FDA) has granted Fast Track Designation for a treatment for  geographic atrophy (GA) secondary to age-related macular degeneration (AMD).  CTx001, developed by biotechnology company Complement Therapeutics, is a novel adeno-associated virus (AAV)-based gene therapy designed to deliver a truncated version of Complement Receptor 1 (mini-CR1). The fast-tracked therapy has… Read More

#News #Regulatory

Screening patient for AMD
#AMD #Clinical trial #Complement Therapeutics #FDA #Gene therapy #Geographic atrophy #Ophthalmology

FDA clears gene therapy trial in geographic atrophy

The US Food and Drug Administration (FDA) has cleared Complement Therapeutics’ Investigational New Drug (IND) application for CTx001, the company’s lead gene therapy candidate.   The IND clearance enables initiation of the Opti-GAIN Phase I/II clinical trial in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).   CTx001… Read More

#News #Regulatory

Test for AMD
#Dry AMD #Geographic atrophy #Ophthalmology #PulseSight Therapeutics

Data support transferrin vectorised therapy for geographic atrophy

New data have revealed the potential of a DNA plasmid expressing human transferrin for the treatment of dry age-related macular degeneration (AMD) and geographic atrophy (GA). PulseSight Therapeutics shared the data on its lead programme PST-611 at the European Association for Vision and Eye Research (EVER)… Read More

#News

Eye
#AMD #Endogena Therapeutics #FDA #Geographic atrophy #Ophthalmology

FDA gives green light for AMD treatment trials

The US Food and Drug Administration (FDA) has granted clearance for Endogena's Investigational New Drug (IND) application for EA 2351, a potential treatment for geographic atrophy (GA). GA is an advanced form of age-related macular degeneration (AMD). The first-in-human study is set to commence in 2024. The company is currently… Read More

#News #Regulatory

Structure of the eye
#AMD #Boehringer Ingelheim #CDR-Life #Collaboration #Geographic atrophy #Ophthalmology #Phase I trial

Antibody treatment for geographic atrophy enters clinical trials

Collaborators Boehringer Ingelheim and CDR-Life have commenced a Phase I evaluation of BI 771716, their antibody fragment-based treatment developed to preserve the vision of people with geographic atrophy (GA). Boehringer Ingelheim and CDR-Life entered a licensing agreement in May 2020 and announced the… Read More

#Editor's Choice #News

Test for AMD
#AMD #Astellas Pharma #FDA #Geographic atrophy #Ophthalmology

FDA approves Izervay for geographic atrophy

The US Food and Drug Administration (FDA) has approved Izervay (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The new complement C5 inhibitor is the only approved GA treatment with a statistically significant reduction in the rate of GA progression at… Read More

#News #Regulatory

Eye
#Antibody Fragments #Boehringer Ingelheim #CDR-Life #Geographic atrophy #Ophthalmology

Antibody fragment-based drug could slow geographic atrophy

CDR-Life has reached a development milestone with its antibody fragment-based drug candidate that could significantly slow down the progression of geographic atrophy (GA). Boehringer Ingelheim and CDR-Life entered a collaboration and licensing agreement in May 2020 and announced the selection of an antibody fragment-based therapeutic candidate… Read More

#News

Eye
#AMD #Aviceda Therapeutics #Geographic atrophy #Nanomedicine / nanotechnology #Ophthalmology #Phase II trial

Novel glycan-coated nanoparticle enters trials for geographic atrophy

Aviceda Therapeutics has dosed the first patient in its Phase II SIGLEC trial investigating AVD-104 as a treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). AVD-104 is a novel glycan-coated nanoparticle, supported by a strong pre-clinical in vivo efficacy and safety profile. Read More

#News

#Anxiety disorder #Diabetes #Drug development #Drug discovery #Geographic atrophy #HIV #Lung cancer #Oncology

Podcast: This week’s drug discovery highlights

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Each of our top five stories this week exemplify the scientific curiosity that fuels the drug… Read More

#News

#Anxiety disorder #Diabetes #Drug development #Drug discovery #Geographic atrophy #HIV #Lung cancer #Oncology

This week in drug discovery (24-28 April)

News round-up for 24-28 April by DDW Digital Content Editor Diana Spencer. Each of our top five stories this week exemplify the scientific curiosity that fuels the drug discovery sector, ultimately leading to better treatments for patients. The stories cover the efforts by research teams to… Read More

#News

Test for AMD
#AI / data analytics / healthtech / informatics #Boehringer Ingelheim #Collaboration #Geographic atrophy #Partnership #RetinaAI

Partners use AI tools to advance novel drugs for geographic atrophy

A partnership between RetinAI Medical and Boehringer Ingelheim aims to improve patient outcomes in geographic atrophy (GA) by combining RetinAI’s Discovery platform and AI tools with Boehringer Ingelheim’s research in retinal diseases. GA is a progressive, advanced form of age-related macular degeneration and a leading cause of complete loss of… Read More

#Business & Investment #News

Screening patient for AMD
#Clinical research #Complement Therapeutics #Dry AMD #Gene therapy #Geographic atrophy #Ophthalmology

Non-interventional geographic atrophy study launches

Complement Therapeutics (CTx) has enrolled the first patient in its study of people diagnosed with geographic atrophy (GA).  The research will support the clinical development of CTx001, CTx’s lead gene therapy asset for the treatment of GA, by enabling the identification of patients with complement-driven AMD for future… Read More

#News

#Covid-19 #Geographic atrophy #Immunology / Virology & Vaccines #Malaria #Neuroscience #Psychedelics

Catch up on the latest DDW Highlights episode

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  In a week that saw magic mushrooms making the… Read More

#News

#Covid-19 #Covid-19 vaccine #Drug development #Drug discovery #Gene therapy #Geographic atrophy #Malaria #Monoclonal antibodies #Psychedelics #Treatment-resistant depression

This week in drug discovery (31 October – 4 November)

News round-up for 31 October – 4 November by DDW Digital Content Editor Diana Spencer  In a week that saw magic mushrooms making the headlines in the UK, we also reported on exciting potential new therapies for geographic atrophy and malaria prevention. Meanwhile, the quest to understand… Read More

#News

MHRA
#AAV #Geographic atrophy #MHRA #Therapeutics

Green light for potential AAV gene therapy 

Complement Therapeutics’ lead asset CTx001, an AAV-based gene therapy for the treatment of geographic atrophy (GA), has been awarded an Innovation Passport by the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA).  CTx001 was awarded the Innovation Passport based on three criteria: that the condition addressed is seriously debilitating with… Read More

#News #Regulatory